Biological
Biological Products clinical trials
- studies test it
- 27
- open now
- 8
- in phase 3
- 3
- first study started
- 2004
Keep track of what changes. Save the Biological Products studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
- BCG
- 1
Studies by the year they started
27 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 12
- Phase 3
- 3
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 17
West China Hospital (2) · National Environment Agency, Singapore (2) · Immune Cell, Inc. (2) · AskBio Inc (1) · Bruce Cree (1) · BioNTech SE (1) · University Hospital, Lille (1) · Steven E Arnold, MD (1)
Often tested with
Tested in the same studies.
Vaccines (3) · Afatinib (2) · Tislelizumab (1) · BNT162 Vaccine (1) · BCG Vaccine (1) · Recombinant Human Papillomavirus 11-valent Vaccine (1) · Melphalan (1) · Inodiftagene vixteplasmid (1)
Studies
Open first, then newest update. How each study uses Biological Products is read from its arms, and is right about nine times in ten.
Testing it · 27
- Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA TreatmentRecruitingNot applicableHospices Civils de LyonNCT07213323Written as Probiotics (Natural product)
- Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid TumorsRecruitingPhase 1Kyushu UniversityNCT05608148Written as Biological
- Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal CancerNot yet recruitingPhase 1The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07735065Written as Biological/Vaccine
- Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological TherapyRecruitingPhase 4Universitaire Ziekenhuizen KU LeuvenNCT05169593Written as Biological Drug
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantRecruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT06832410Written as Biological/Vaccine
- Impact of IIT-SIT on Dengue ClustersRecruitingNot applicableNational Environment Agency, SingaporeNCT06894901Written as Biological (Male Wolbachia-infected Aedes aegypti)
- CD30 Targeted CAR-T in Treating CD30-Expressing LymphomasRecruitingPhase 1Immune Cell, Inc.NCT03383965Written as ICAR30 T cells
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and LeukemiaRecruitingPhase 1Immune Cell, Inc.NCT03383952Written as ICAR19 CAR-T cells
- A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWithdrawnPhase 1West China HospitalNCT06741982Written as Lysogenic HSV virus.
- A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)Active, not recruitingPhase 2AskBio IncNCT06285643Written as AAV2-GDNF gene therapy
- Clinical Trial of GAIA-102 for Advanced and Relapse NSCLCTerminatedPhase 1/2GAIA BioMedicine Inc.NCT05207371Written as Biological
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple SclerosisActive, not recruitingPhase 1Bruce CreeNCT06451159Written as KYV-101 (Biological) - 0.33 ×10^8 cells
- A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaActive, not recruitingPhase 1/2West China HospitalNCT07010120Written as Lysogenic HSV virus.
- Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy ChildrenCompletedPhase 3BioNTech SENCT04816643Written as Biological/Vaccine: BNT162b2 10mcg
- Biological Meshes in Infected Fields: a Randomized Controlled TrialCompletedPhase 3University Hospital, LilleNCT01594450Written as Biological mesh
- Impact of Project Wolbachia - Singapore on Dengue IncidenceCompletedNot applicableNational Environment Agency, SingaporeNCT05505682Written as Biological (Male Wolbachia-infected Aedes aegypti)
- A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate ADCompletedPhase 2Steven E Arnold, MDNCT05004688Written as Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
- Validation of the In-utero Transmission of ProbioticsCompletedPhase 2Centre de recherche du Centre hospitalier universitaire de SherbrookeNCT04050189Written as Natural products: Probiotics
- Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA TrialWithdrawnPhase 2Longeveron Inc.NCT02587572Written as Peripheral Intravenous (IV) infusion of LMSCs
- Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)CompletedPhase 2National Vaccine and Serum Institute, ChinaNCT04436133Written as Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Codes
What other systems call Biological Products · ClinicalTrials.gg INT007075
- MeSH (NLM) D001688Biological ProductsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D001688 | Biological Products | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.